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Abstract
The mammalian target of rapamycin (mTOR) regulates cell growth by integrating nutrient and
growth factor signaling and is strongly implicated in cancer. But mTOR is not an oncogene, and
which tumors will be resistant or sensitive to new ATP-competitive mTOR inhibitors now in
clinical trials remains unknown. We screened a panel of over 600 human cancer cell lines to
identify markers of resistance and sensitivity to the mTOR inhibitor PP242. RAS and PIK3CA
mutations were the most significant genetic markers for resistance and sensitivity to PP242,
respectively; colon origin was the most significant marker for resistance based on tissue type.
Among colon cancer cell lines, those with KRAS mutations were most resistant to PP242, while
those without KRAS mutations most sensitive. Surprisingly, cell lines with co-mutation of
PIK3CA and KRAS had intermediate sensitivity. Immunoblot analysis of the signaling targets
downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242
was correlated with inhibition of phosphorylation of the translational repressor 4E-BP1, but not
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tribosomal protein S6. In a tumor growth inhibition trial of PP242 in patient-derived colon cancer
xenografts, resistance to PP242 induced inhibition of 4E-BP1 phosphorylation and xenograft
growth was again observed in KRAS mutant tumors without PIK3CA co-mutation, compared to
KRAS WT controls. We show that, in the absence of PIK3CA co-mutation, KRAS mutations are
associated with resistance to PP242 and that this is specifically linked to changes in the level of
phosphorylation of 4E-BP1.
Keywords
mTOR; colon cancer; PIK3CA; KRAS; xenograft; PP242
Introduction
Clinically approved kinase inhibitors such as imatinib, vemurafenib, and crizotinib show
strong anti-tumor responses in patients with mutated forms of their target kinases, BCR-
ABL, BRAF V600E, and EML4-ALK, respectively (1–3). The intrinsic sensitivity of cancer
cells expressing these mutationally activated kinase alleles provides a template for patient
selection and clinical trial design (4). However, many of the protein kinase targets currently
being investigated in cancer such as MEK, ERK, AKT, and mTOR are not commonly
mutated, but rather lie at critical nodes in conserved cancer signaling pathways. The design
of clinical trials for experimental therapeutics that inhibit these targets is challenging as
mutations upstream of these nodes may or may not predict sensitivity to inhibition of
downstream kinases (5).
Deregulated mammalian target of rapamycin (mTOR) signaling is present in human diseases
that alter metabolism, including diabetes and cancer (6). An essential and evolutionarily
conserved regulator of cell metabolism, mTOR is the catalytic core of two related
heteromeric protein complexes, mTORC1 and mTORC2 (7–9). In cancer, conserved mTOR
mutations or gene amplifications have not been identified; instead, mTORC1 is activated by
mutations in upstream signaling networks (10,11). The network most implicated in
oncogenic mTORC1 signaling is the PI3K/AKT/TSC pathway (12). Enhanced response to
mTOR inhibition in patients with rare somatic TSC mutations supports the rationale of
targeting this network (13).
Temsirolimus and everolimus, derivatives of the natural product rapamycin, are the only
mTOR inhibitors currently approved for the treatment of solid tumors but their activity is
limited and mechanism of action debated (14,15). A new and potentially more efficacious
class of mTOR inhibitors has been developed specifically to target cancer (16–19). These
small molecule drugs competitively target the ATP binding pocket of the mTOR kinase
domain and have now entered clinical trials (20). The discovery of these molecules allowed
for the division of canonical mTORC1 substrates into classes: those sensitive to inhibition
by rapamycin (p70S6 kinase, S6K; and its direct target ribosomal protein S6, rpS6) and
those that were relatively insensitive to rapamycin (eIF4E Binding Proteins, 4E-BPs).
Inhibition of 4E-BP activity downstream of mTORC1 is responsible for the anti-
proliferative effects of PP242 in cell culture models (21). But it remains unclear whether
rapamycin sensitive or insensitive targets downstream of mTORC1 are the clinically
relevant biomarkers for treatment efficacy.
Colon cancer contains many of the most prevalent aberrations in cancer including KRAS
and PIK3CA (phosphatidylinositol 3-kinase catalytic subunit alpha) mutations and loss of
PTEN (phosphatase and tensin homolog) expression (22). The frequency of these mutations
makes it possible to study how each contributes to resistance and sensitivity to molecularly
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ttargeted therapies (23). Here we used a high-throughput cell-screening platform to identify a
genetic signature for primary resistance of colon cancer to the ATP-competitive mTOR
inhibitor PP242. We validated these observations in cultured cell lines and primary human
tumor xenografts and identified a biomarker for PP242 efficacy.
Results
Screening of cancer cell lines
We identified markers of resistance or sensitivity to the ATP-competitive mTOR inhibitor
PP242 in solid tumor cell lines. Our approach relied on automated screening of growth of
solid tumor cell lines that were annotated for common oncogenic mutations and tissue of
origin (Tables S1 and S2) (24). The cell line set (n=666) was treated with 500 nM PP242
and assayed for growth inhibition at 72 hours (The complete data set is available as an
online supplement). The PP242 treatment results were normally distributed (Shapiro-Wilk
test, p= 0.145) and centered upon 57.9% of untreated control providing maximal sensitivity
to detect both resistant and sensitive cell lines. Significant differences were observed in the
response of cell lines grouped by tissue of origin (Fig. 1A and Table S1). Several cell types
had mean PP242 responses that were greater than 0.5 standard deviations from the complete
set. Cell types that were significantly sensitive to PP242 treatment included nervous system,
stomach, kidney and non-small cell lung cancer (NSCLC). Only three types were
significantly resistant: bone, cervix and colon. Of all significantly resistant and sensitive cell
types, colon was distinct for its combination of large magnitude of resistance (0.59 standard
deviations higher than the population mean) and the significance of this difference
(p=0.005).
For a subset of cell lines (n=357), we used information from the Sanger COSMIC (http://
www.sanger.ac.uk/genetics/CGP/cosmic/) database of cancer cell lines to annotate
mutations in 15 of the most common oncogenes (Table S2). We analyzed the role of these
mutations in accounting for sensitivity or resistance to PP242 by two independent methods.
Multivariate linear regression of all genotypes against PP242 growth response showed that
RAS and PIK3CA were significant and independent predictors of resistance and sensitivity,
respectively (test statistics from the regression analysis: RAS, p=0.045; PIK3CA, p=0.017).
We also tested whether RAS and PIK3CA mutations were significantly enriched in the
population of the most sensitive and resistant cell lines (Fig. 1B). PIK3CA mutations were
absent in the 10% most PP242 resistant cell lines while enriched in the 10% most sensitive
ones (Fisher’s exact test: resistant cell lines, p=0.0048; sensitive cell lines, p=0.013). In the
most PP242 sensitive cell lines, the reduced number of RAS mutations was significant
(Fisher’s exact test: p=0.030), but the enrichment of mutants in resistant cell lines was not
(p=0.35). Compared to prior studies that examined responsiveness to inhibitors targeting a
specific genetic lesion (such as lapatinib and the EGFR mutant L858R) (24), the strength of
the correlation between either PIK3CA or RAS mutation and resistance or sensitivity to
PP242 was modest.
Knowing that RAS was a modest marker of resistance to PP242, we asked if the high
frequency of RAS mutations in colon cancer might account for the degree of PP242
resistance observed in this tumor type. KRAS mutant colon cell lines were significantly
more resistant than wild-type (WT) colon cancer cell lines (Fig. 1C). Interestingly, the
resistance of RAS mutant cell lines to PP242 observed within the screening set appears to be
driven by RAS mutant pancreas and colon cancer cell lines; RAS dependent resistance was
not observed in NSCLC. To quantify the degree of resistance to PP242 imparted upon colon
cancer cell lines by KRAS mutations, we determined the half maximal inhibitory
concentration (IC50) for a subset of cell lines (Fig. 1D). The potency (IC50) of PP242 in
colon cell lines varied widely from 90 nM to 8 μM (Table 1). KRAS mutant colon cell lines
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twere significantly more resistant to PP242 than WT cell lines (p=0.0036; unpaired t-test).
The most PP242 resistant cell line, SW620 (IC50 =8 μM) is mutant for KRAS. Of special
note were KRAS mutant cell lines with intermediate sensitivity to PP242. This group of cell
lines had both KRAS mutations and PIK3CA mutations and their responsiveness to PP242
was closer to that of sensitive cell lines than the resistant ones. The most sensitive colon
cancer cell lines were all WT for KRAS. To identify a mechanism for the varied
responsiveness of colon cancer cells to PP242, analysis of the downstream effectors of
mTOR was performed.
mTORC1 substrates 4E-BP1 and rpS6 are differentially inhibited by PP242
To ascertain the signaling alterations that lead to the spectrum of responses to PP242 in
colon cancer cells, we examined whether mTOR substrate phosphorylation was
differentially inhibited in resistant versus sensitive cell lines. Three representative cell lines
were studied: SW620 (Mut for KRAS), HCT 15 (Mut for both KRAS and PIK3CA) and
SW48 (WT for KRAS and PIK3CA) (Fig. 2A). In PP242-sensitive HCT 15 and SW48 cell
lines, 1 hour of treatment with PP242 similarly reduced the phosphorylation of mTORC1
substrates S6K and 4E-BP1, as well as mTORC2 substrate AKT S473. We were surprised to
observe that in the PP242-resistant cell line SW620, mTORC1 substrates were differentially
inhibited by PP242. Phosphorylation of S6K and its effector rpS6 were potently inhibited by
PP242, as in the PP242-sensitive cell line HCT 15, but the phosphorylation of 4E-BP1 was
poorly inhibited even at high drug concentrations. Expression levels of 4E-BP1 or basal
amounts p-4E-BP1 did not correlate with response to PP242 in the cell lines examined (Figs.
2A and S1A). Resistance of 4E-BP1 to dephosphorylation was observed in other KRAS
mutant colon cancer cell lines as well (Fig. S1B). We performed the same western blot
analysis with 2 additional active site mTOR inhibitors: KU-0063794, which is based on a
different chemical scaffold from PP242 (19), and MLN0128 (previously INK128), a clinical
derivative of PP242 (25). In both cases, 4E-BP1 phosphorylation was less potently inhibited
in SW620 cells compared to HCT 15 cells, as was observed with PP242 (Figs. S1C and
S1D).
Differential inhibition of mTOR substrates has previously been observed with rapamycin
where inhibition of phosphorylation of mTORC1 substrates bifurcates between sensitive
(rpS6) and insensitive (4E-BP1) targets. Rapamycin has no short-term activity against
mTORC2 and incompletely inhibits mTORC1; it fails to inhibit 4E-BP1 phosphorylation
while paradoxically increasing AKT phosphorylation (26). All of these effects were visible
in the KRAS mutant colon cancer cell line HCT 15 (Fig. 2B). Feedback activation of AKT
has also been observed in human trials with rapamycin derivatives (27). Unlike rapamycin,
PP242 suppressed feedback activation of AKT over 24 hours and fully inhibited cell growth
(Figs. S2A and S2B). These findings add to work in colon and other cell types showing that
the more complete inhibition of mTOR by PP242 results in greater inhibition of cell growth
than that achieved by rapamycin (28–30).
To quantify the sensitivity of 4E-BP1 phosphorylation to inhibition by PP242 and relate it to
cell growth, phosphoprotein IC50 curves were constructed (Fig. 2C). The IC50 for inhibition
of phosphorylation of rpS6 was similar in HCT 15 and SW620 cell lines (72 and 212 nM
respectively, a 3-fold difference). Conversely, the IC50 values for inhibition of 4E-BP1
phosphorylation were 0.43 μM for HCT 15 cells and 10 μM for SW620 cells. The IC50
values for 4E-BP1 phosphorylation and the difference between cell lines (23-fold)
correspond closely to the growth IC50 values (0.30 μM and 7.8 μM, a 26-fold difference).
Immunofluorescence imaging of p-4E-BP1 and p-rpS6 in treated SW620 and HCT 15 cells
established that rpS6 is excluded from the nucleus in both cell lines and is similarly inhibited
(Fig. 2D). p-4E-BP1 partitions between the cytoplasm and nucleus as previously described
Ducker et al. Page 4
Oncogene. Author manuscript; available in PMC 2014 September 20.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(31). Differential inhibition of 4E-BP1 phosphorylation by PP242 between cell lines was not
correlated with a difference in subcellular localization of 4E-BP1 (Figs. 2D and S3). Single
cell analysis showed no PP242 resistant subpopulation within the SW620 cell line that
would account for the differences in sensitivity (Fig. S3). The consistent inhibition of S6K
target rpS6 in SW620 and HCT 15 cells demonstrates that PP242 enters the cells and binds
mTOR with similar efficacies.
MAPK signaling differences do not alter mTORC1 substrate specificity
Our finding that KRAS mutant colon cancer cell lines exhibit distinct patterns of substrate
inhibition by PP242 led us to question whether outputs of the mitogen activated protein
kinase (MAPK) pathway were impacting downstream mTOR substrates. It is known that the
mTORC1 component raptor is phosphorylated by the ERK substrate, p90RSK, and we
examined whether inhibition of this effect would impact mTOR dependent phosphorylation
of 4E-BP1 and rpS6 (32). Immunoblotting revealed that expression of raptor and the
phosphorylation of mTOR is greater in the resistant SW620 cell line compared to sensitive
HCT 15 cells, however phosphorylation of raptor appeared to be equivalent (Fig. 3A).
MAPK pathway activation as assayed by ERK phosphorylation was also comparable
between the two KRAS mutant cell lines regardless of PIK3CA mutation status.
Pharmacological inhibition of the MAPK pathway by the MEK inhibitor PD0325901
potently inhibited cell growth in KRAS mutant SW620 cells (33), without impacting
mTORC1 signaling in either SW620 or HCT15 cells (Fig. 3A and 3B). In contrast,
inhibition of phosphorylation of p90RSK by FMK-MEA (34,35), did not affect mTORC1
substrate phosphorylation, (Fig. 3A) or cell growth, even at high concentrations (Fig. 3C).
The MAPK pathway does not directly alter the phosphorylation of mTOR substrates in
colon cancer.
Combination treatment of PD0325901 and an AKT inhibitor leads to profound growth arrest
and synergistic inhibition of 4E-BP1 phosphorylation (36). We asked whether the
combination of PP242 and a MAPK inhibitor would similarly lead to enhanced suppression
of phosphorylation of 4E-BP1. By itself, acute treatment with PP242 modestly increased
phosphorylation of ERK, and significantly increased phosphorylation of p90RSK and
consequently raptor, suggesting that MAPK combination therapy could be useful (Fig. 3A).
This effect was most prominent in the PP242 resistant SW620 cells. Combination treatment
of PP242 and PD0325901 was additive and at least partly mTOR independent (Fig. 3B).
However, addition of PD0325901 did not increase the inhibition of phosphorylation of 4E-
BP1 beyond what was achieved with PP242 in both resistant and sensitive cell lines (Fig.
3A). There was no additive benefit in treatment combining FMK-MEA with PP242 (Fig.
3C). Thus the enhanced inhibitory effects of combining PP242 with PD0325901 on cell
growth are not due to increased inhibition of mTOR substrates but rather ERK substrates
that are independent of p90RSK.
MAPK signaling did not explain the differential sensitivity of KRAS mutant colon cancer
cell lines to PP242, so we examined RAS directly. Mutations activate RAS by biasing the
fraction in the active GTP-bound form. This conformation can be selectively pulled down
using a GST tagged RAS binding domain (RBD) taken from c-RAF-1 (37). We observed
that the amount of RAS-GTP pulled down differed among KRAS mutant cell lines and was
inversely correlated with sensitivity to PP242 (Fig. 3D). KRAS WT and PP242-sensitive
cell line SW48 had non-detectable amounts of RAS-GTP in the basal state, yet KRAS
mutant cell lines HCT 15, SW480 and SW620 had progressively more RAS-GTP. Our
experiment differentiates KRAS mutant cell lines by levels of RAS-GTP and shows a
correlation between this activation and resistance to mTOR inhibition by PP242. This was
not accompanied by a similar trend in MAPK pathway activation, suggesting that other RAS
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teffectors may be responsible for transmitting the mTOR resistance phenotype observed in
high RAS-GTP cells.
Mutant PIK3CA but not PTEN loss leads to mTOR inhibitor sensitization
Phosphoinositide signaling in colon cancers is deregulated by both loss of PTEN expression
(35%) and activation of PIK3CA (15%) (38,39). Our observation that KRAS mutant cell
lines with PIK3CA mutations were sensitive to PP242 led us to investigate how changes in
phosphoinositide signaling impact the sensitivity of mTOR to PP242. A previous analysis of
PTEN status in breast cancer cell lines observed no correlation between PTEN expression
and PP242 sensitivity (40). Our analysis of PTEN in the complete PP242 cell screen
similarly showed no relation between PTEN mutations and PP242 sensitivity, but this
analysis was confined to the small subset of PTEN mutant tumors whereas loss of
expression is more often accomplished via epigenetic mechanisms. All of our cell lines
express PTEN, and because loss of PTEN can activate AKT signaling, we wanted to test
whether reduction of PTEN would sensitize cells to PP242. Using siRNA directed against
PTEN, a 96-hour knockdown was performed and the cells were analyzed for their response
to PP242 (Fig. 4A). PTEN knockdown modestly increased p-AKT S473 levels but did not
change the dose response on either mTORC1 substrate. Our results are consistent with prior
studies showing that PTEN and PIK3CA activate mTOR signaling downstream of AKT in
non-redundant ways.
To determine if mutant PIK3CA is sufficient to sensitize SW620 cells to PP242, we
transfected SW620 cells with constructs of the most common PIK3CA mutations. Mutations
in PIK3CA cluster into two conserved “hotspots”: a kinase domain hotspot, most commonly
H1047R, and helical domain mutations, most commonly E542K or E545K (41). As
previously shown, the PIK3CA kinase domain mutant was more transforming than the
helical domain mutations and conferred a substantial growth advantage to the cells (Fig. S4)
(42).
We treated the PIK3CA and KRAS co-mutant isogenic cell lines with PP242 and analyzed
phospho-signaling. The basal phosphorylation of both AKT T308 and S473 was
significantly higher in the H1047R mutant than either the WT or the helical domain E542K
mutant expressing cells (Fig. 4B). The inhibition of phosphorylation of the mTOR substrate
4E-BP1 was only significantly altered in the H1047R mutant expressing cell line. Activated
AKT signaling sensitized KRAS mutant cells to mTOR inhibition consistent with the
response of mTORC1 substrate 4E-BP1 to acute pharmacological inhibition. To confirm the
relationship between 4E-BP1 inhibition and cell growth, SW620 PIK3CA mutant cell
growth was assayed and the PP242 IC50 was determined. The values of 10 and 11 μM for
the E542K and WT lines were nearly identical to the measured SW620 parental cell line (8
μM) whereas the H1047R cell line was approximately 8-fold more sensitive to PP242 (Fig.
4C).
KRAS mutation status predicts response to PP242 in human primary xenografts
We sought to validate our cell line observations about PP242 sensitivity and KRAS and
PIK3CA mutation status in an in vivo model of human colon cancer, patient-derived
xenografts. Such xenografts allow patient tumors to be maintained in vivo without
undergoing the irreversible changes that occur upon in vitro culture (43). Patient-derived
xenografts overcome many of the problems that render standard cell line and cell line
derived xenografts models poorly predicative of clinical response (44,45). Their utility in
colon cancer was recently demonstrated by the identification of a genetic marker of
resistance to the anti-EGFR antibody cetuximab (46).
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tXenografts were established from liver metastases of patients with colon cancer resected
with curative intent (47) (Table S3). Non-diagnostic portions of removed metastases were
implanted, characterized and subsequently passaged in athymic nude mice (Figs. S5A, S5B
and S6).
To determine the effects of PP242 in patient-derived xenografts with genetic lesions
common in colon cancer, three different patient-derived tumors representing three different
combinations of mutant PIK3CA and KRAS were analyzed: WT KRAS and WT PIK3CA
(CR 698); Mut KRAS and WT PIK3CA (CR 702); Mut KRAS and Mut PIK3CA (CR 727)
(Table S3). Cohorts of single tumor-bearing mice were treated once daily with PP242 or
vehicle for 30 days or until (control) tumor burden had reached protocol limits. Treatment
was tolerated (Fig. S7).
PP242 slowed tumor growth compared to control (Fig. 5A). In trials with either WT or
double mutant tumors (CR 698 and CR 727, respectively), the decrease in tumor growth
between treatment and control arms was apparent after seven days. This was in contrast to
the more modest effect of PP242 in the KRAS single mutant tumor (CR 702), where the
difference in tumor growth was only significant after 28 days. In no trial did PP242 lead to
significant tumor regression (>50% in volume) in an individual mouse, but stable disease
(final tumor volume of −50% to +20% of starting) was achieved in 26% of mice with CR
698 or CR 727 tumors (and no mice with CR 702 tumors). In PP242 responsive tumors, the
growth inhibitory effects were not accompanied by a histological change in tumor
characteristics.
To directly compare the separate trials and better understand the differences between the
resistant KRAS mutant tumor CR 702, and sensitive tumors CR 727 and CR 698, we fit the
trial data to a linear mixed effects model. Using the model, we obtained a daily tumor
growth rate for each treatment condition and compared the effect of PP242 on tumor growth
rate (Fig. 5B). Differences in tumor growth rate between xenografts could not be
independently excluded as contributing to the treatment effect, but molecular data strongly
suggest that the effects were related to mTOR inhibition. The effect of PP242 treatment on
tumor growth was highly significant as determined by a Wald test for both the CR 698 trial
(p <0.001) and CR 727 trial (p=0.001) but not for the CR 702 trial (p =0.123). Further
comparison of the magnitude of the PP242 treatment effect showed that mTOR inhibition
was significantly more effective in the CR 698 trial than the CR 702 trial, (p=0.04) but that
the difference in treatment effect was not statistically significant between CR 702 and CR
727 (Fig. 5C).
Inhibition of 4E-BP1 and not rpS6 correlates with anti-tumor effect of PP242
To identify a basis for the differential effect of PP242 on tumor growth, we conducted
phospho-signaling analysis by quantitative western blotting (Fig. 5D). Western blots showed
an unambiguous inhibition of p-rpS6 in all PP242-treated samples indicating that mTOR
was at least partially inhibited in all trials and that PP242 was able to access the tumors
equally. The phosphorylation of substrate 4E-BP1 was differentially inhibited among the
different trials. p-4E-BP1 was significantly inhibited in the CR 698 and CR 727 trials, but
not CR 702. Immunohistochemical staining for p-4E-BP1 was preformed on select tumors,
and the results were consistent with the western blotting (Fig. S8). Percent inhibition of
p-4E-BP1, not p-rpS6, linearly correlated with tumor growth inhibition (Fig. 5E).
These trials showed a striking primary resistance to PP242 treatment in a KRAS mutant
tumor (CR 727) that was not evident in either a tumor with wild type KRAS or a tumor with
a PIK3CA mutation in addition to KRAS.
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The ability to identify determinants of primary resistance to targeted therapies undergoing
clinical development has the potential to provide a benefit to patients by guiding patient
selection and development of effective biomarkers. We approached this study with the
hypothesis that upstream inputs of mTOR that are mutated would affect sensitivity to mTOR
inhibitors. Our large cell screen showed that the average sensitivity of different tumors types
varied significantly, reflecting the different genetic make-ups of these cancers. Additionally,
we were encouraged to find significant positive and negative correlations to PP242 efficacy
with mutations in PIK3CA and KRAS, respectively. Newly published data validates our
approach showing that PI3KCA H1047R mutations are predictive of response to rapamycin
based mTOR inhibitors in patients (48). We chose to examine colon cancer in detail because
both mutations implicated in sensitivity and resistance are present and the extreme resistance
to mTOR inhibitors in KRAS mutant colon cancer cell lines was unique.
Differences in sensitivity to PP242 among tumors and cell lines were linked to differences in
the sensitivity of mTOR substrates to pharmacological inhibition of their phosphorylation.
What was unexpected about our findings was the decoupling of inhibition of mTORC1
substrates 4E-BP1 and rpS6 by an ATP-competitive mTOR inhibitor. The phosphorylation
status of 4E-BP1 is a better indicator of the functional state of mTOR than S6K and closely
correlates with the growth arrest caused by mTOR inhibition. In the single mutant KRAS
patient-derived xenograft and cell lines, the inhibition of mTORC1 substrates by PP242 is
similar to that of rapamycin, which is now well established to block p-rpS6 but not p-4E-
BP1 by a still unknown mechanism. Our observation that in certain cell lines, an ATP-
competitive inhibitor could produce these rapamycin like differential inhibitory effects,
suggests that a common mechanism may underlie these phenomena.
To test the hypothesis that activated PIK3CA signaling conferred sensitivity to mTOR
inhibition, even in a mutant KRAS background, isogenic cell lines were created that differed
only by their PIK3CA mutation status. Increased sensitivity to PP242 was only observed in
the cell line containing an AKT activating PIK3CA mutation. This result adds to a
significant set of data that shows that upstream AKT mutations sensitize tumors to mTOR
inhibition. The resistance driven by mutant KRAS is not reversible by short-term MAPK
inhibition, leading us to conclude that phosphorylation changes regulating mTORC1 do not
affect substrate accessibility. Our observation that resistance is correlated with RAS-GTP
loading functionally differentiates cell lines with KRAS mutations, and suggests that the
mechanism of resistance is directly KRAS driven but independent of MAPK signaling.
Concurrent to our work on primary resistance to ATP-competitive mTOR inhibitors, other
groups have recently reported mechanisms of acquired resistance to these agents. In a study
of human mammary epithelial cells treated at sublethal doses of the dual PI3K/mTOR
inhibitor BEZ235, Roberts and coworkers identified MYC amplification in one cell line and
eIF4E amplification in another cell line (49). Sonenberg and coworkers characterized PP242
resistant E1A/Ras-clones generated by growing the cells for two months in drug (50). The
emergent clones exhibited down regulation of 4E-BP1 and 2 or overexpressed eIF4E,
highlighting the importance of monitoring the ratio of 4E-BPs and eIF4E in tumors to assess
likely responses to ATP-competitive mTOR inhibitors. These two studies on emergent
resistance further highlight the importance of translational regulation in response to mTOR
inhibitors.
Owing to the lack of direct inhibitors of KRAS, considerable effort has been made to
uncover druggable targets (such as kinases TBK1 and STK33) that might act in a synthetic
lethal manner with KRAS mutant tumors (51). Our study reveals a different approach to the
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tsame goal, that of finding a small molecule that is effective even in a setting of KRAS
mutant tumors. We find that the presence of a second oncogene, PI3KCA, provides a signal
that sensitizes the KRAS mutant tumors to an ATP-competitive mTOR inhibitor. This result
is surprising because the presence of a second lesion typically provides the cancer with a
bypass mechanism to avoid kinase inhibitor sensitivity (52). Of note is that 3 of the 4 RAS
mutant cell lines that were among the 10% most sensitive to PP242 also harbored a PIK3CA
mutation.
In the context of colon cancer, a solid tumor in which small molecule kinase inhibitors have
yet to achieve significant clinical utility, our findings suggest subsets of patients who may
benefit from targeted anti-mTOR therapy. First, mutations in PIK3CA are likely to be
sensitive to mTOR inhibition. The importance of selectively treating mutant PI3KCA colon
cancer patients has been highlighted by a retrospective analysis demonstrating that low dose
aspirin (by an as yet unclear mechanism) can dramatically prolong survival in those patients
(53). Additionally, patients with WT KRAS are likely to be responsive to mTOR inhibitors.
Furthermore, we believe that among colon cancer patients with mutant KRAS, those with
concomitant hyperphosphorylation of AKT induced by mutant PIK3CA may benefit from
ATP-competitive mTOR inhibitors. Finally, although rpS6 remains the default biomarker
for mTOR inhibitors, our study shows that the phosphorylation status of 4E-BP1 may be a
more relevant biomarker of treatment efficacy for ATP-competitive inhibitors.
Materials and Methods
Inhibitors
The mTOR inhibitors PP242 and MLN0128 were synthesized from commercially available
starting materials as previously reported (16,25). Rapamycin and PD0325901 were
purchased from EMD-Millipore chemicals (Billerica, MA). FMK-MEA was a gift of Jack
Taunton (UC San Francisco, San Francisco, CA).
Cell Screen
The automated cell screen was performed using PP242 (500 nM) as previously described
(24). Complete results from the PP242 screen are available as a supplementary file (Data file
S1).
Cell culture
Cell lines were purchased from the American Type Tissue Collection (ATCC, Manassas,
VA) and cultured according to their recommendations in antibiotic-free media.
Cell proliferation assay
Cells were plated on 96-well plates at densities between 2500 and 5000 cells/well. Cell
growth was assayed using resazurin sodium salt (Sigma, Saint Louis, MO) and measured
using a Safire bottom-reading fluorescent plate reader with excitation at 530 nm and
emission at 590 nm.
Western blot analysis
Cells were grown in 6 or 12-well plates and treated with inhibitor(s) or vehicle (0.1% or
0.2% DMSO for single or combination drug assays, respectively) for 1 h unless otherwise
noted. Cells were then lysed in radio-immunoprecipitation assay buffer (RIPA); lysates were
normalized for protein content using a Bradford assay (absorbance at 595 nm), resolved by
SDS-PAGE, transferred to nitrocellulose and blotted. Phosphorylation-specific antibodies
were purchased from Cell Signaling Technology (Danvers, MA), except for phospho-raptor
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tS722 (Millipore) and visualized by HRP or fluorescent secondary antibodies. Quantitative
western blotting was accomplished using fluorescent secondary antibodies (800 nm
emission) for visualization using an Odyssey IR scanner from LI-COR Biosciences
(Lincoln, NE). All reported band intensities were internally normalized to β-Actin and each
experiment was done in independent biological duplicates.
Immunofluorescence
Cells were plated on fibronectin treated glass-bottom 12-well plates, drug treated and then
fixed and stained following standard protocols (Cell Signaling Technology). An Alexa Fluor
488 conjugated goat anti-rabbit secondary antibody (Life Technologies, Carlsbad, CA) was
used to visualize the cells using a Zeiss Axiovert 200M fluorescence microscope. Nuclei
were counterstained with Hoechst 33342 dye (Pierce). Image analysis was conducted with
the software suite MetaMorph.
GST-RBD Pull Down
Assay was adapted from a protocol published with the Pierce active RAS pull down and
detection kit (#16117). Cells were lysed in HEPES lysis buffer (40 mM HEPES pH 7.4, 150
mM NaCl, 0.1% Tx-100). GST Pull down was conducted according to protocol using
purified GST-RBD-c-Raf-1 and glutathione beads (GE Healthcare, Pittsburgh, PA). Pan
RAS antibody was from Epitomics (Burlingame, CA).
siRNA
Pooled siRNA against PTEN (SMARTpool PTEN) or control scramble siRNA was
purchased from Millipore. siRNA was transfected using DharmaFECT 2 reagent according
to manufacture’s instructions (Thermo Scientific Dharmacon Products, Lafayette, CO). 96 h
after transfection, cells were treated with drugs and western blotted.
Mutant PIK3CA SW620 cell lines
Mutant p110α expressing SW620 lines were created by retroviral infection using a pMIG-
p110α plasmid as previously reported (54).
Patient-derived xenografts
The research protocol was approved by the Committee on Human Research of the
University of California, San Francisco (UCSF) and patient consent was obtained. All
animal studies followed a protocol approved by the UCSF Animal Care and Use Committee.
To establish xenografts, excess tumor removed during hepatic resection was minced under
sterile conditions to generate pieces approximately 4–8 mm3. These were dipped into sterile
matrigel (BD Biosciences, Sparks, MD) and implanted subcutaneously (SC) onto the flanks
of female athymic mice (FOXN1 nude, Harlan, Indianapolis, IN). Non-implanted pieces
were flash-frozen in liquid nitrogen and banked. For each tumor, 2–4 pieces were implanted
into 2–3 mice to establish the initial xenograft passage. When tumor volume reached ~1,000
mm3, mice were sacrificed; tumors were divided and implanted SC into new animals.
Drug treatment
PP242 was prepared as a 25 mg/mL suspension in 3.1% NMP, 81.6% PVP, 15.3% H2O. 100
μL of PP242 suspension (2.5 mg/dose equal to 100mg/kg) or vehicle alone was given orally
once daily. For drug efficacy trials, mice bearing single tumors were treated for 30 days or
when tumors reached 3000 mm3 and then sacrificed and tumors were harvested.
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tHistologic analysis of xenograft tumors
4 μm sections prepared from FFPE tissue were stained with hematoxylin & eosin (H & E)
and submitted for review by the pathologist, J.P.S.
Sequencing
DNA extracted from surgical specimens with the Qiagen tissue kit (Qiagen, Valencia, CA)
was sequenced using standard Sequenom platform protocols (Sequenom, San Dieg, CA) and
colon cancer-specific mutational panel (ColoCarta) (55). iPLEX well 6, containing KRAS-
Q61L and HRAS-Q61L primers was omitted.
Statistical analyses
Statistical tests and curve fitting was conducted using the programs Stata and Prism.
Univariate and multivariate regressions were conducted using the default analysis models in
Stata. Comparison of means was conducted using two-tailed Student’s t tests. Data from
drug treatment trials was fit to a linear mixed effects model as previously described (56)
using Stata. Wald tests determined whether the slopes differed for different treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
An unbiased cell screen reveals factors leading to resistance and sensitivity to the ATP-
competitive mTOR inhibitor PP242 (A) Colon cell origin is a strong predictor for resistance
to PP242 treatment. The mean response of each cell type to 500 nM PP242 treatment was
plotted as a standard deviation from the population mean. The y-axis indicates the
significance of the test-statistic for each independent difference in means (cell type versus
population). The size of the circle corresponds to the number of cell lines of each type
analyzed. Colon origin (n=39) was the strongest single predictor of resistance or sensitivity
to PP242 among all annotated organ types. (B) PIK3CA mutations are prevalent in cell lines
sensitive to PP242 while RAS marks cell lines that are resistant to PP242. The set of 357
cell lines with known mutation status for PIK3CA and RAS were assayed for growth
inhibition and ranked according to the inhibition results. The 10% most resistant and most
sensitive cell lines are shown here in order of increasing response to PP242. (C) KRAS
mutant colorectal cells are more resistant to PP242 than cells harboring WT KRAS.
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selected colon cancer cell lines. KRAS mutant cell lines with concomitant PIK3CA
mutations are more sensitive to PP242 than KRAS mutants alone.
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mTORC1 substrates are differentially inhibited in PP242 resistant versus sensitive cell lines
(A) 4E-BP1 is differentially inhibited in PP242 resistant and sensitive colon cancer cell
lines. Representative cell lines SW620, HCT 15 and SW48 were treated with PP242 or
rapamycin (20 nM) for 1 hour and analyzed by western blotting. (B) Differential inhibition
is reminiscent of incomplete mTORC1 inhibition by rapamycin. In HCT 15 cells, rapamycin
only partially inhibits 4E-BP1 phosphorylation after a 1 hour treatment, despite potently
blocking rpS6 phosphorylation. (C) Quantification of mTORC1 substrate inhibition shows
that inhibition of p-4E-BP1 and not inhibition of p-rpS6 tracks with growth inhibition.
Quantification was performed on western blots of lysed cells after treatment for 1 hour with
increasing PP242 concentrations in two independent experiments. (D) Immunofluorescence
of mTORC1 substrates reveals consistent subcellular localization despite differential
inhibition by PP242. SW620 and HCT 15 cells were treated with increasing concentrations
of PP242 for 1 hour, formalin fixed and stained for either p-4E-BP1 or p-rpS6 (both green)
and counterstained with DAPI (blue). PP242 treatment does not alter the subcellular
localization of either phosphorylated substrate.
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Inhibition of MAPK signaling does not alter mTORC1 substrate phosphorylation (A)
Treatment of cell lines with MAPK inhibitors does not sensitize mTOR substrates to PP242
inhibition. Cells were treated with the MEK inhibitor PD0325901 (20 nM), the p90RSK
inhibitor FMK-MEA (3 μM), PP242 (1 μM) singly or in combination for 1 hour. Neither
FMK-MEA nor PD0325901 sensitize mTOR substrates to PP242 treatment. (B–C)
Inhibition of ERK but not p90RSK augments the cell growth arrest induced by PP242. The
MEK inhibitor PD0325901 is a potent inhibitor of cell growth, but selective inhibition of
ERK substrate p90RSK by FMK-MEA does not recapitulate this phenotype in a three-day
cell growth assay measured using a resazurin assay. (D) RAS-GTP loading, but not MAPK
pathway activation, correlates with resistance to PP242. Glutathione pull down of RAS-GTP
with GST-RBD shows high RAS-GTP levels in unstimulated KRAS mutant PP242 resistant
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tcell lines. Significantly different levels of RAS-GTP activation were observed within KRAS
mutant cells.
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PIK3CA mutation but not PTEN loss sensitizes KRAS mutant cells to PP242 (A) siRNA
against PTEN does not sensitize KRAS mutant CRC cells to PP242. SW620 cells were
treated with siRNA against PTEN for 72 hours prior to 1 hour drug treatment with PP242
(3.0, 1.0, 0.33 and 0.1 μM). (B) Addition of mutant PIK3CA to the KRAS mutant cell line
SW620 increases sensitivity to PP242. Retroviral insertion of either WT PIK3CA, helical
(E542K) or kinase (H1047R) domain mutations only resulted in elevated basal AKT
activation in the H1047R case. Cells were treated with rapamycin (20 nM) or PP242 (3.0,
1.0, 0.3 μM) for 1 h before lysis. (C) IC50s for SW620 cell lines engineered to contain
additional PIK3CA mutations.
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KRAS mutant patient-derived xenografts are resistant to PP242 by incomplete inhibition of
4E-BP1 phosphorylation. (A) Percent growth curves of three xenografts show differences in
response to PP242 treatment. KRAS and PIK3CA genotypes are as follows: CR 698 (KRAS
WT/PIK3CA WT), CR 702 (KRAS Mut/PIK3CA WT), CR 727 (KRAS Mut/PIK3CA Mut).
Mice were given 100 mg/kg PP242 once daily or vehicle for the indicated time. Tumors
were normalized to 100 percent at the beginning of dosing and percent growth ±SEM was
plotted for each day when tumor volume measurements were taken. Asterisks indicate
significant differences in tumor growth at each measurement point as determined by an
unpaired t-test (* p< .05, ** p< .01, *** p< .001). (B) Treatment effect is significant in
tumors CR 698 and CR 727. Tumor growth rates were calculated using a linear mixed
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teffects model. PP242 led to a significant reduction in growth rate as calculated using a Wald
test (asterisks represent the same p values as in A) in the KRAS WT tumor CR 698 and the
double mutant tumor CR 727, but not the KRAS single-mutant tumor CR 727. (C) PP242 is
most effective at inhibiting growth of the KRAS WT tumor CR 698. Comparison of the
growth rate difference calculated from the model shows that PP242 is significantly more
effective at inhibiting growth in CR 698 than in CR 702. The growth rate difference is the
growth rate of the PP242 treated tumors minus the control growth rate. All other
comparisons were not statistically significant. (D) Whole-tumor western blots show that
p-4E-BP1 levels were significantly more reduced by PP242 treatment in KRAS WT and
KRAS/PIK3CA double mutant tumors but not in KRAS single-mutant tumors. After
treatment with either PP242 or vehicle for 30 days, tumors were removed and analyzed by
western blot for phosphoprotein analysis. Bands were quantified by fluorescent antibodies
and intensities internally normalized to those of β-actin. Intensities are reported as arbitrary
normalized fluorescence units. Statistical comparisons were made using two-tailed t-tests as
in Figure 3A. (E) Changes in p-4E-BP1 but not p-rpS6 correlate with changes in tumor
growth. A plot of the tumor growth rate difference (Figure 5C) versus percent inhibition of
p-4E-BP1 and p-rpS6 shows that the efficiency in inhibiting 4E-BP1 phosphorylation
correlates linearly with the percent growth defect between treated and untreated tumors.
Percent inhibition of p-rpS6 does not vary significantly with genotype or tumor growth
defect as calculated from linear mixed effects model.
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Table 1
KRAS and PIK3CA mutations modulate sensitivity to mTOR inhibition
Cell Line
Mutational Status
PP242 (μM)
KRAS PIK3CA bRAF
SW620 G12V WT WT 7.8
SW480 G12V WT WT 4.6
SK-CO-1 G12V WT WT 4
LS-513 G12D WT WT 3.9
SW1116 G12A WT WT 0.84
LS-174T G12D H1047R WT 0.84
HCT 116 G13D H1047R WT 0.41
HCT 15 G13D E545K WT 0.3
COLO 205 WT WT V600E 0.24
HT-29 WT WT V600E 0.23
COLO 201 WT WT V600E 0.23
Caco-2 WT WT WT 0.22
SW48 WT WT WT 0.09
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